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INTRODUCTION
The relevance of colorectal adenocarcinoma
lies in its high incidence, with the liver being the
organ most frequently affected by distant
metastases.1-2 Liver metastases occur in 40 to 50%
of patients with colorectal adenocarcinoma, ac-
counting for approximately 80% of deaths in the
first three postoperative years. Nevertheless, de-
spite this, they are occasionally susceptible to cura-
tive treatment.3-4 The relevance of studies that seek
the early diagnosis of such lesions is obvious. Di-
agnosis is particularly based on imaging techniques
which, despite relevant advances, still present limi-
tations, particularly with regard to very small le-
sions.5-6 Tumor markers are a further method that
can be used in the diagnosis of liver metastases; in
the case of colorectal adenocarcinoma,
carcinoembryonic antigen (CEA) is the marker
most widely used.7 It is conventionally determined
in serum and, although being the most sensitive
and specific, it is rather limited in the diagnosis of
the primary tumor.8 Despite its increased sensi-
tivity in the presence of liver metastases, it remains
limited in cases of initial lesions.9 Owing to such
limitations, several authors have studied CEA lev-
els in gallbladder bile, aiming to improve their
sensitivity and specificity for the diagnosis of liver
metastases at earlier stages.10-19 This study aimed
to verify the correlation between CEA levels in
gallbladder bile and the presence of liver metastases
in patients with colorectal adenocarcinoma.
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METHODS
The procedures that follow were in ac-
cordance with the ethical standards of the
committee responsible for human experimen-
tation and with the Helsinki Declaration of
1975, as revised in 1983.
From December 1993 to February 1996,
45 patients hospitalized in the Surgical Gas-
troenterology Discipline ward with a diagno-
sis of colorectal adenocarcinoma were enrolled.
Patients with associated diseases, such as chole-
lithiasis, obstruction of the biliary pathways,
intestinal inflammatory diseases, chronic or
acute liver diseases and pancreatitis, were not
included. For the classification of patients with
and without liver metastases, three
preoperative parameters were used, based on
imaging techniques (computer tomography
[CT], magnetic resonance [IRM] and com-
puted arterial portography7 [CTAP]) and
intraoperative assessment. Thus, group I,
which included 30 patients without liver
metastases, and group II, which included 15
patients with liver metastases were created.
Eighteen organ-donor patients were used as
the control group. None had cholelithiasis,
obstruction of the biliary pathways, cirrhosis,
liver schistosomiasis or pancreatitis. With re-
gard to gender, the control group was com-
posed of 13 males and 5 females, with ages
ranging from 19 to 66 years, mean age 35.6
years. In group I, 9 males and 21 females were
studied, with ages ranging from 28 to 83 years,
mean age 57.2 years; whereas in group II, 7
males and 8 females were studied, with ages
ranging from 30 to 80 years, mean age 58.3
years (Table 1).
As for Dukes classification,20 Group I was
composed of 6 patients presenting Dukes A
classification, 8 Dukes B, 12 Dukes C, and 4
were not classified as they underwent no
tumor resection.
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CONTEXT: The relevance of colorectal adenocarcinoma
lies in its high incidence, with the liver being the
organ most frequently affected by distant metastases.
Liver metastases occur in 40 to 50% of patients with
colorectal adenocarcinoma, accounting for approxi-
mately 80% of deaths in the first three postopera-
tive years. Nevertheless, despite this, they are oc-
casionally susceptible to curative treatment.
OBJECTIVE: The present investigation focused on the rela-
tionship between the level of carcinoembryonic antigen
(CEA) in gallbladder bile and the presence of liver
metastases secondary to colorectal adenocarcinoma.
DESIGN: Diagnostic test study.
SETTING: Surgical Gastroenterology Discipline at the
São Paulo Hospital, São Paulo, Brazil.
SAMPLE: Forty-five patients with colorectal adenocarci-
noma were studied, 30 without liver metastases (group
I), and 15 with liver metastases (group II). Diagnosis
of liver metastases was made through computed to-
mography, magnetic resonance imaging and com-
puted tomography during arterial portography. Sam-
ples of peripheral blood, portal system blood, and
gallbladder bile were collected from patients during
the surgical procedure. A control group composed
of 18 organ donors underwent the same material
collection procedures. CEA level determination was
made through fluoroimmunoassay.
RESULTS: Mean CEA value in peripheral serum was
2.0 ng/ml (range: 0.7 to 3.8 ng/ml) in the control
group, 11.4 ng/ml (range: 0.5 to 110.3 ng/ml) in
group I, and 66.0 ng/ml (range: 2.1 to 670 ng/ml)
in group II. In the portal system, serum mean values
found were 1.9 ng/ml (range: 0.4 to 5.0 ng/ml) in
the control group, 15.3 ng/ml (range: 0.8 to
133.3 ng/ml) in group I, and 70.8 ng/ml (range:
1.8 to 725 ng/ml) in group II. Mean values found in
gallbladder bile were 4.1 ng/ml (range: 1.0 to
8.6 ng/ml) in the control group, 14.3 ng/ml (range:
zero to 93.0 ng/ml) in group I, and 154.8 ng/ml
(range: 14.0 to 534.7 ng/ml) in group II.
CONCLUSIONS: The CEA level in gallbladder bile is
elevated in patients with liver metastases. Determina-
tion of CEA both in peripheral serum and in gallblad-
der bile enabled patients with liver metastases to be
distinguished from those without such lesions. The level
of CEA in gallbladder bile, however, seems to lead
to a more accurate diagnosis of liver metastases sec-
ondary to colorectal adenocarcinoma.
KEY WORDS: Carcinoembryonic antigen (CEA). Bile.
Metastases. Liver. Adenocarcinoma.
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Forty-one patients were submitted to IMR
and CTAP in addition to CT. The 4 patients
who failed to undergo CTAP already presented
liver metastases detected by CT and IMR.
Imaging was always analyzed by two single ex-
aminers from the Imaging Diagnosis Depart-
ment, who considered the scanning either posi-
tive or negative, according to the presence or
absence of images suggesting liver metastases.
The surgical inventory was made by the surgeon
following the collection of both gallbladder bile
and portal system blood. Following the macro-
scopic assessment of the liver, bimanual palpa-
tion was performed. Whenever the surgeon had
any doubt, biopsy of the lesion was performed.
Peripheral venous blood was collected
during anesthetic induction, by direct punc-
ture of an upper limb vein. Ten ml was col-
lected into a dry tube, which was centrifuged
to separate serum.
At surgery, all patients were submitted to
material collection soon after the abdominal
cavity was opened, prior to the handling of
the tumor or to the surgical inventory. In the
control group, bile collection was performed
before the liver was excised. Gallbladder bile
was collected by puncture of the gallbladder
fundus after a purse string suture using ab-
sorbable material.
All collected material was centrifuged and
the separated serum was stored in a freezer at -
20 ºC, until level determination was performed.
The CEA level determination in serum was
performed by using the Delfia® method.
The Kruskal-Wallis test21 was used, sepa-
rately, to compare every CEA level found in
the peripheral serum, portal system serum and
bile among the groups studied. The Friedman
test22 was used to compare CEA levels in the
peripheral serum, portal system serum and
bile, between each other, within each group.
Whenever a statistically significant difference
among the groups was detected, the multiple
comparisons test was applied to identify the
difference. The level of significance of the tests
applied was 5% (0.05) for rejection of the null
hypothesis.
In order to determine the optimal nor-
mality limit value for CEA levels in bile, i.e.
the value which distinguished the control
group patients from those with colorectal ad-
enocarcinoma, a ROC (receiver operating
characteristic) curve was drawn.23 Likewise, in
order to decide what the best cutoff point was
for the CEA level in bile and for the CEA level
in peripheral serum, allowing groups I and II
to be distinguished, two further ROC curves
were drawn. To compare the level of CEA in
bile with the level of CEA in peripheral se-
rum, the corresponding ROC curve areas were
matched by using a non-parametric test,
whose level of significance was 5% (a ≤ 0.05)
for rejection of the null hypothesis.
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RESULTS
CEA levels obtained in peripheral serum
were as follows: in group I patients, values
ranged from 0.5 to 110.3 ng/ml (mean: 11.4
ng/ml; standard deviation: 24.6 ng/ml); in
group II patients, values ranged from 2.1 to
670.0 ng/ml (mean: 66.0 ng/ml; standard
deviation: 168.8 ng/ml) and in the control
group patients, values ranged from 0.7 to 3.8
ng/ml (mean: 2.0 ng/ml; standard deviation:
0.9 ng/ml). No significant difference was
found between values obtained in group I and
the control group. However, such values were
significantly lower than the ones obtained in
group II (P= 0.0002) (Table 1).
CEA levels obtained in bile were as fol-
lows: in group I patients, values ranged from
zero to 93.0 ng/ml (mean: 14.3 ng/ml; stand-
ard deviation: 18.0 ng/ml); in group II pa-
tients, values ranged from 14.0 to 534.7 ng/
ml (mean: 154.8 ng/ml; standard deviation:
193.0 ng/ml) and in the control group pa-
tients, values ranged from 1.0 to 8.6 ng/ml
(mean: 4.1 ng/ml; standard deviation: 2.0 ng/
ml). No significant differences were found
between values obtained in group I and the
control group. However, such values were sig-
nificantly lower than the ones found in group
II (P= 0.00000006) (Table 2).
CEA levels found in bile were significantly
higher than the ones found in peripheral serum in
the three groups studied, with the following values
found for groups I, II and the control:
P = 0.033, P = 0.001 and P = 0.0001, respectively.
The cutoff point for the CEA level in
bile was 7.0 ng/ml, as this CEA level deter-
mined the largest area under the curve: 0.79
(Figure 1). Sensitivity found for this value
was 63.3%, and specificity was 94%. Bile
CEA levels tested were those close to the ones
Table 1. Distribution of mean, maximum
and minimum values and standard devia-
tion of CEA levels in peripheral serum
 control  Group I  Group II
n 16 30 15
mean 2.0 11.4 66.0
standard deviation 0.9 24.6 168.8
minimum 0.7 0.5 2.1
maximum 3.8 110.3 670.0
Table 2. Distribution of mean, maximum
and minimum values and standard
deviation of CEA levels in bile
Control  group I  group II
n 18 30 15
Mean 4.1 14.3 154.8
Standard deviation 2.0 18.0 193.0
Minimum 1.0 0.0 14.0
Maximum 8.6 93.0 534.7 Figure 1. ROC curve to determine the level of CEA in bile (groups I and control).
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that presented optimal sensitivity and
specificity in relation to the presence of
colorectal adenocarcinoma in the 48 patients
studied in groups I and control.
Two CEA levels in bile determined the
largest areas under the curve: 14.0 and 20.0
ng/ml, with an area of 0.87. For the 14.0
ng/ml limiting value, sensitivity found was
100% and specificity was 73.3. For the 20.0
ng/ml cutoff point, sensitivity found was
86.7% and specificity 86.7%. Three CEA
values in peripheral serum presented the
largest areas under the ROC curve: 2.0, 8.0
and 12.5 ng/ml, with an area of 0.73 (Fig-
ure 2). For the 2.0 ng/ml cutoff point, sen-
sitivity found was 100% and specificity
46.7. For the 8.0 ng/ml cutoff point, sensi-
tivity found was 66.7% and specificity
80.6%. For the 12.5 ng/ml cutoff point,
sensitivity found was 60% and specificity
86.7%. Comparison between the areas of
the ROC curves, drawn to determine the
best cutoff points to determine CEA levels
in bile and to determine CEA in the periph-
eral serum, showed a significant difference
(P = 0.009) (Figure 2).
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DISCUSSION
CEA in peripheral serum was found to
allow no distinction between patients in the
control group from those without liver
metastases, i.e. CEA in peripheral blood is not
a good diagnosis test. This agrees with other
studies in the literature24-25 that show CEA in
peripheral serum to be of little sensitivity and
specificity in cases of early colorectal adeno-
carcinoma. It was also found that CEA in pe-
ripheral serum allowed patients with liver
metastases to be distinguished from those
without liver metastases. This finding also
agrees with data found in the literature16-24
showing improved sensitivity in the presence
of liver metastases. CEA levels in bile showed
the same statistical behavior as CEA in pe-
ripheral serum, i.e. they allowed no diagnosis
of colorectal adenocarcinoma, but it was pos-
sible to distinguish patients with liver
metastases from those without liver metastases.
The distinction in this latter case had more
efficacy, due to increased sensitivity and
specificity. Statistical corroboration lies in the
significant difference found between the ROC Figure 2. ROC curve to determine the level of CEA in bile and in peripheral serum.
curves areas for both levels. And why is CEA
in bile better able to detect liver metastases
than CEA in peripheral serum? According to
some authors,17, 19, 21 tumor cell products, with
CEA among them, would be more concen-
trated in smaller amounts of bile than in larger
amounts of serum and, furthermore, bile
would be more exposed to such tumor prod-
ucts. These are plausible explanations, but
there is controversy regarding the origin of
CEA in bile, as CEA in bile may arise, at least
in part, from the primary tumor.26 Experimen-
tal studies on the production, circulation, liver
clearance and release of CEA in bile27, 28, 29
speak out against such possibility, although
there are no studies on the release of CEA in
bile in humans. A suggestion for studies that
may solve such controversies, and which has
already been presented by other authors,23 is
to determine the level of CEA in bile prior to
and following resection of the primary tumor.
A further issue which calls for discussion
is that of false-positive results regarding CEA
levels in bile, i.e. the patients without liver
metastases who presented elevated CEA lev-
els in bile. One of the possibilities is again
the origin of CEA in the primary tumor, and
a further possibility is cross-reactions. The
existing methods are known to be adequate
for determining CEA in serum, and failures
may occur when they are used to determine
CEA in bile.10, 11, 16, 18, 30 However, the most
striking possibility for explaining elevated
levels of CEA in bile in patients without de-
tected liver metastases may relate to occult
liver metastases.31-32 The only way to clear up
such doubt is to follow up the patients with-
out detected metastases who present high
levels of CEA in bile, by performing serial
tests to trace the appearance of such lesions.
And why would it be important to know
whether CEA in bile is predictive of the ap-
pearance of liver metastases? Because accord-
ing to some authors,10-12, 14-16, 18 such a group
of patients may benefit from some kind of
prophylactic treatment to avoid the devel-
opment of liver metastases.
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CONCLUSIONS
The main conclusion of this study is that
CEA in bile increases in the presence of liver
metastases secondary to colorectal adenocar-
cinoma. Second, it may be concluded that
CEA in bile is better than CEA in peripheral
serum for the diagnosis of liver metastases.
Two further questions remain to be answered
in subsequent studies. One deals with the ori-
gin of CEA in bile and the other one con-
cerns the false-positive results.
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CONTEXTO: A importância do adenocarci-
noma colorretal está na sua alta incidência,
sendo o fígado o órgão mais freqüentemente
acometido por metástases à distância. As
metástases hepáticas ocorrem em 40 a 50%
dos pacientes portadores de adenocarcinoma
colorretal e são responsáveis por cerca de 80%
das mortes nos três primeiros anos de pós-
operatório; mas, apesar disso, eventualmente
são passíveis de tratamento curativo.
OBJETIVO: Verificar a correlação entre os valores de
CEA na bile vesicular e a presença de metástases
hepáticas por adenocarcinoma colorretal.
TIPO DE ESTUDO: Estudo de teste
diagnóstico.
LOCAL: Disciplina de Gastroenterologia Cirúrgica
do Hospital São Paulo, São Paulo, Brasil.
AMOSTRA: 45 pacientes portadores de adeno-
carcinoma colorretal, dos quais 30 foram
classificados como não portadores de
metástases hepáticas (grupo I) e 15 como
portadores de metástases hepáticas (grupo II).
O diagnóstico de metástases hepáticas foi feito
por tomografia computadorizada, ressonância
magnética e porto tomografia compu-
tadorizada. Durante a cirurgia, os pacientes
foram submetidos à coleta de sangue
periférico e bile da vesícula biliar. Um grupo
controle composto por 18 pacientes doadores
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RESUMO
de órgãos foi submetido aos mesmos
procedimentos de coleta de material. A
dosagem de CEA foi feita por método
imunofluorimétrico.
RESULTADOS: A média dos valores de CEA
obtidos no soro periférico foi 2,0 ng/ml (0,7
a 3,8 ng/ml) no grupo controle; 11,4 ng/ml
(0,5 a 110,3 ng/ml) no grupo I e 66,0 ng/ml
8 ng/ml (2,1 a 670 ng/ml) no grupo II. No
soro do sistema portal, a média dos valores
obtidos foi 1,9 ng/ml (0,4 a 5,0 ng/ml) no
grupo controle; 15,3 ng/ml (0,8 a 133,3 ng/ml)
no grupo I e 70,8 ng/ml (1,8 a 725 ng/ml) no
grupo II. Na bile, a média observada foi 4, 1 ng/
ml (1,0 a 8,6 ng/ml); 14,3 ng/ml (zero a 93,0
ng/ml) e 154,8 ng/ml (14,0 a 534,7 ng/ml),
respectivamente, para os três grupos.
CONCLUSÕES: Os valores de CEA na bile estão
elevados em pacientes portadores de metástases
hepáticas. Através, tanto da dosagem de CEA
no soro periférico, quanto na bile, foi possível
diferenciar pacientes sem metástases hepáticas
daqueles portadores de tais lesões. A dosagem
de CEA na bile, no entanto, foi mais acurada
no diagnóstico de metástases hepáticas por ad-
enocarcinoma colorretal.
PALAVRAS-CHAVE: Antígeno cárcino-
embriônico (CEA). Bile. Metástase. Fígado.
Adenocarcinoma.
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